<DOC>
	<DOCNO>NCT02337387</DOCNO>
	<brief_summary>The purpose study evaluate tolerability two different formulation blosozumab woman reach menopause . This study last approximately 12 week participant , include screen . Screening require within 28 day prior start study .</brief_summary>
	<brief_title>A Study 2 Different Formulations Blosozumab ( LY2541546 ) Post Menopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<criteria>Part A : Overtly healthy postmenopausal ( PMP ) females Part B : PMP woman currently take oral bisphosphonates prevention treatment osteoporosis Have body mass index ( BMI ) screen 19.0 35.0 kilogram per square meter ( kg/m^2 ) Have know allergy blosozumab , constituent , relate compound Have abnormality 12lead electrocardiogram ( ECG ) History breast carcinoma Fracture long bone within 1 year screening Have use teriparatide within 3 year prior screen</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>